← Browse by Condition
Medical Condition

prostate cancer metastatic castration resistant

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT07179783 Phase 2
Recruiting

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Enrollment
28 pts
Location
China
Sponsor
Tianjin Medical University Sec...
View Trial →